The Disease
Every organ system, including the lungs, heart, kidney, and liver, can be affected by fibrosis, a pathologic condition characterized by excessive accumulation of connective tissue components and loss of organ functional characteristics, leading frequently to high morbidity and mortality.
Our Preclinical Testing Tools
The bleomycin induced pulmonary fibrosis is a reliable preclinical tool standardized and validated in C57BL/6 mice.
Scleroderma pathology features are successfully reproduced in an osmotic mini pump bleomycin release mouse model.
Read-Out Parameters
Body weight changes as indicators of successful pathology induction
Histopathological evaluation of H&E and Masson’s trichromy stained tissue sections
SP-D protein serum levels as pulmonary fibrosis biomarker
Bronchoalveolar lavage cytokine/chemokine or haematological analysis
Fibronectin, Col1a1 and αSma tissue expression levels as fibrosis markers
Validated platform
Bleomycin induced pulmonary fibrosis
Intratracheal administration of bleomycin induces pulmonary fibrosis while longterm slow release of bleomycin induces a systemic pathology with scleroderma skin phenotypes. No efficient treatment of fibrosis is available, nintedanib allows partial amelioration of it.
Competitive Advantage
Pulmonary fibrosis and scleroderma standardized preclinical platforms in combination to our unceasing interest for the development of anti fibrotic treatments support efficiently anti fibrotic drug development projects.
